Fulgent Genetics (FLGT) Capital Expenditures (2015 - 2026)

Fulgent Genetics has reported Capital Expenditures for 12 years, with the latest figure at $3.9 million in Q2 2026.

• Quarterly Capital Expenditures fell 43.48% year-over-year to $3.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.1 million (down 42.37% YoY) and the FY2025 annual result came in at $22.6 million, down 44.01% from the prior year.
• Capital Expenditures retreated to $3.9 million in Q2 2026 per FLGT's latest filing, from $5.2 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $19.5 million in Q3 2024 and troughed at $2.0 million in Q1 2023.
• A 5-year average of $6.3 million and a median of $5.0 million in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures surged 296.85% in 2024, then slumped 69.03% in 2025.
• Over 5 years, Capital Expenditures stood at $4.7 million in 2022, then plunged by 34.22% to $3.1 million in 2023, then climbed by 21.64% to $3.8 million in 2024, then soared by 31.82% to $5.0 million in 2025, then declined by 22.53% to $3.9 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $3.9 million, $5.2 million, and $5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.